JMI Laboratories, North Liberty, IA, USA.
JMI Laboratories, North Liberty, IA, USA.
Diagn Microbiol Infect Dis. 2021 May;100(1):115302. doi: 10.1016/j.diagmicrobio.2020.115302. Epub 2020 Dec 29.
Ceftolozane/tazobactam is an antipseudomonal cephalosporin combined with a β-lactamase inhibitor. Ceftolozane/tazobactam has been approved in >60 countries for treating complicated urinary tract infections, acute pyelonephritis, complicated intra-abdominal infections (with metronidazole), and hospital-acquired pneumonia, including ventilator-associated pneumonia in adults. We analyzed susceptibilities for 35,882 gram-negative isolates collected from patients in 35 US medical centers from 2012 to 2018. The rate of multi-drug resistant Enterobacterales was stable (9.5%-10.1%), while the P. aeruginosa multi-drug resistance rate increased from 15.5% in 2012 to 22.9% in 2018. The carbapenem-resistant Enterobacterales rates varied from 0.9% to 2.2% and extended-spectrum β-lactamase phenotypes increased from 10.5% to 16.8%. The most active drugs against P. aeruginosa were ceftolozane/tazobactam (95.8%-97.5% susceptible) and amikacin (93.9%-98.0%); against Enterobacterales, amikacin (97.9%-98.8%), meropenem (97.7%-98.8%), and ceftolozane/tazobactam (93.3%-95.6%) were the most active. These data suggest that ceftolozane/tazobactam has effective in vitro activity against organisms causing serious gram-negative infections.
头孢洛扎/他唑巴坦是一种抗假单胞菌头孢菌素与β-内酰胺酶抑制剂的复方制剂。头孢洛扎/他唑巴坦已在超过 60 个国家获得批准，用于治疗复杂性尿路感染、急性肾盂肾炎、复杂性腹腔内感染（联合甲硝唑）和医院获得性肺炎，包括成人呼吸机相关性肺炎。我们分析了 2012 年至 2018 年来自美国 35 个医疗中心的 35882 株革兰氏阴性菌分离株的药敏结果。多药耐药肠杆菌科的发生率保持稳定（9.5%-10.1%），而铜绿假单胞菌的多药耐药率从 2012 年的 15.5%上升至 2018 年的 22.9%。耐碳青霉烯类肠杆菌科的发生率从 0.9%到 2.2%不等，超广谱β-内酰胺酶表型的发生率从 10.5%上升至 16.8%。对铜绿假单胞菌最有效的药物是头孢洛扎/他唑巴坦（敏感率为 95.8%-97.5%）和阿米卡星（93.9%-98.0%）；对肠杆菌科，阿米卡星（97.9%-98.8%）、美罗培南（97.7%-98.8%）和头孢洛扎/他唑巴坦（93.3%-95.6%）最有效。这些数据表明头孢洛扎/他唑巴坦对引起严重革兰氏阴性感染的病原体具有有效的体外活性。
